Select Language

HLA-A*02:01 & B2M & Peptide (KVLEHVVRV)

Product Inquiry

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Mertuzumab		Phase 3 Clinical	Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University	Coronavirus Disease 2019 (COVID-19); Carcinoma, Non-Small-Cell Lung	Details
Meplazumab	HI6H8	Phase 3 Clinical	Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University	Malaria; Coronavirus Disease 2019 (COVID-19); Malaria, Falciparum	Details
Anti-CD147 CAR T cell therapy (Xijing Hospital)		Phase 1 Clinical		Glioblastoma	Details
CD147-CAR T cell therapy (Peking University People's Hospital)		Phase 1 Clinical	Peking University People'S Hospital	Lymphoma, T-Cell	Details
89Zr-CD147		Phase 1 Clinical		Solid tumours	Details

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Iodine[131I] Metuximab		Approved	Chengdu Huasun Biotechnology Co Ltd	Licartin, 利卡汀	Mainland China	Carcinoma, Hepatocellular	Chengdu Huasun Biotechnology Co Ltd	2006-10-12	Carcinoma, Hepatocellular	Details